Podcasts about Sano

Con las divulgadoras en nutrición Yolanda Vélaz y María Marqués 

Today's MadTech Daily covers Netflix pulling out of the bidding war for Warner Bros, Dentsu naming Takeshi Sano as global CEO, and HubSpot expanding its media reach with a Starter Story deal.

In this episode, Jason and Makenzie sit down with Steve Thornton and Eric Harris of Monte Sano Research Corporation (MSRC) to discuss the company's evolution to employee ownership. They reflect on their company's journey to an ESOP and how succession was intentionally embodied well before the formal transition, and the cultural foundations that made ESOP alignment a natural fit. The conversation also explores how employee ownership can bridge founders to successors, along with candid advice for leaders considering this path, including preparation, key decisions, and lessons learned along the way.

-Esta noche tendremos con nosotros a Enrique Echazarra, conocido y reconocido investigador, escritor y divulgador especializado en temas de misterio, historia y fenómenos anómalos. Con él hablaremos de su trayectoria y de esas; “4 décadas de escepticismo sano” -Con nuestra compañera, Ana Theysser, nos adentraremos en “La Puerta Oculta”, para que nos hable de “Lo que hay que saber de los muertos” -En Historias, Cuentos y Leyendas, vamos a tener a nuestro compañero, el Investigador, Escritor y Divulgador Paco López Mengüal, que en “Vida de Santos” nos narrará la Historia de “San Vitores” -Y terminaremos con nuestro DEBATE, con nuestros contertulios Francisco agudo, Alfonso Sánchez Hermosilla y Salvador Sandoval, debatiremos sobre un interesante y más que controvertido tema, “Cátaros, ¿Buenos cristianos o Herejes?” “El camino es largo y está a punto de comenzar… Compinches de la noche, poneos cómodos, agudizad las orejas que empezamos…” Por FACEBOOK: https://www.facebook.com/Nemesis-Radio-1550831935166728/ Podcast de NEMESIS RADIO: http://www.ivoox.com/podcast-podcast-nemesis-radio_sq_f1133446_1.html CANAL MISTERIOS DE IVOOX: https://www.ivoox.com/escuchar-canal-misterios-ivoox_nq_2594_1.html Canal misterios de Ivoox: https://www.facebook.com/canalmisteriosdeIvoox/ YOU TUBE: https://www.youtube.com/channel/UC7PD6Knea7eWw88rLp0vR0w E-MAIL: nemesisradiomurcia@gmail.com Por Internet a través de nuestras webs: frecuenciamurcia.es (NEMESIS RADIO NO SE HACE RESPONSABLE DE LOS COMENTARIOS DE LOS CONTERTULIOS E INVITADOS QUE PARTICIPAN EN DICHO PROGRAMA) DIRIGEN Y PRESENTAN ANTONIO PÉREZ Y JOSÉ ANTº MARTÍNEZ

Clase del 24 de febrero del 2026

Sano y Veracruzano - Cáncer de Mama CEDICAM by Radiotelevisión de Veracruz

Hoog (ranglijst-) bezoek voor de mannen vandaag; Wilco van Schaik, de algemeen directeur van NEC schuift aan. Want dit weekend staat de kraker tegen de rood-groen-zwarten op het programma. In punten staan beiden gelijk... en de Champions League is het ultieme doel. Heeft Ajax eigenlijk nog een kans om Sano binnen te hengelen? Worden de Nijmegenaren een structurele concurrent? Dat en nog veel meer in deze aflevering van de Kale en Kokkie podcast.

Venezuela tiene las mayores reservas de petróleo del mundo, pero la industria estatal ha estado desprovista de inversiones durante muchos años.

Luis Herrero entrevista a Luis Miguel Real, psicólogo y autor del libro "La mentira de la fuerza de voluntad".

Sano y Veracruzano - Círculo de Mujeres y Autocuidado by Radiotelevisión de Veracruz

Yordi Rosado conversa con la especialista en medicina funcional Nathaly Marcus sobre las claves de su libro Sano, Salvaje y Sabio. En esta plática, exploran de manera general cómo retomar el equilibrio natural del cuerpo y adoptar hábitos que transforman la salud física y mental. ¡No se lo pierdan!See omnystudio.com/listener for privacy information.

Dr. Pedro Barata and Dr. Ugwuji Maduekwe discuss the evolving treatment landscape in gastroesophageal junction and gastric cancers, including the emergence of organ preservation as a selective therapeutic goal, as well as strategies to mitigate disparities in care. Dr. Maduekwe is the senior author of the article, "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?" in the 2026 ASCO Educational Book. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also the deputy editor of the ASCO Educational Book. Gastric and gastroesophageal cancers are the fifth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Over the last decade, the treatment landscape has evolved tremendously, and today, organ preservation is emerging as an attainable but still selective therapeutic goal. Today, I'm delighted to be speaking with Dr. Ugwuji Maduekwe, an associate professor of surgery and the director of regional therapies in the Division of Surgical Oncology at the Medical College of Wisconsin. Dr. Maduekwe is also the last author of a fantastic paper in the 2026 ASCO Educational Book titled "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Prime Time?" We explore these questions in our conversations today.  Our full disclosures are available in the transcript of this episode as well. Welcome. Thank you for joining us today. Dr. Ugwuji Maduekwe: Thank you, Dr. Barata. I'm really, really glad to be here. Dr. Pedro Barata: There's been a lot of progress in the treatment of gastric and gastroesophageal cancers. But before we actually dive into some of the key take-home points from your paper, can you just walk us through how systemic therapy has emerged and actually allowed you to start thinking about a curative framework and really informing surgery decision-making? Dr. Ugwuji Maduekwe: Great, thank you. I'm really excited to be here and I love this topic because, I'm terrified to think of how long ago it was, but I remember in medical school, one of my formative experiences and why I got so interested in oncology was when the very first trials about imatinib were coming through, right? Looking at the effect, I remember so vividly having a lecture as a first-year or second-year medical student, and the professor saying, "This data about this particular kind of cancer is no longer accurate. They don't need bone marrow transplants anymore, they can just take a pill." And that just sounded insane. And we don't have that yet for GI malignancies. But part of what is the promise of precision oncology has always been to me that framework. That framework we have for people with CML who don't have a bone marrow transplant, they take a pill. For people with GIST. And so when we talk about gastric cancers and gastroesophageal cancers, I think the short answer is that systemic therapy has forced surgeons to rethink what "necessary" really means, right? We have the old age saying, "a chance to cut is a chance to cure." And when I started out, the conversation was simple. We diagnose the cancer, we take it out. Surgery's the default. But what's changed really over the last decade and really over the last five years is that systemic therapy has gotten good enough to do what is probably real curative work before we ever enter the operating room. So now when you see a patient whose tumor has essentially melted away on restaging, the question has to shift, right? It's no longer just, "Can I take this out?" It's "Has the biology already done the heavy lifting? Have we already given them systemic therapy, and can we prove it safely so that maybe we don't have to do what is a relatively morbid procedure?" And that shift is what has opened the door to organ preservation. Surgery doesn't disappear, but it becomes more discretionary. Necessary for the patients who need it, and within systems that can allow us to make sure that we're giving it to the right patients. Dr. Pedro Barata: Right, no, that makes total sense. And going back to the outcomes that you get with these systemic therapies, I mean, big efforts to find effective regimens or cocktails of therapies that allow us to go to what we call "complete response," right? Pathologic complete response, or clinical complete response, or even molecular complete response. We're having these conversations across different tumors, hematologic malignancies as well as solid tumors, right? I certainly have those conversations in the GU arena as well. So, when we think of pathologic CRs for GI malignancies, right? If I were to summarize the data, and please correct me if I'm wrong, because I'm not an expert in this area, the traditional perioperative chemo gives you pCRs, pathologic complete response, in the single digits. But then when you start getting smarter at identifying biologically distinct tumors such as microsatellite instability, for instance, now you start talking about pCRs over 50%. In other words, half of the patients' cancer goes away, it melts down by offering, in this case, immunotherapy as a backbone of that neoadjuvant. But first of all, this shift, right, from going from these traditional, "not smart" chemotherapy approaches to kind of biologically-driven approaches, and how important is pCR in the context of "Do I really need surgery afterwards?" Dr. Ugwuji Maduekwe: That's really the crux of the entire conversation, right? We can't proceed and we wouldn't be able to have the conversation about whether organ preservation is even plausible if we hadn't been seeing these rates of pathologic complete response. If there's no viable tumor left at resection, did surgery add something? Are we sure? The challenge before this was how frequently that happened. And then the next one is, as you've already raised, "Can we figure that out without operating?" In the traditional perioperative chemo era, pathologic complete response was relatively rare, like maybe one in twenty patients. When we go to more modern regimens like FLOT, it got closer to one in six. When you add immunotherapy in recent trials like MATTERHORN, it's nearly triple that rate. And it's worth noting here, I'm a health services-health disparities researcher, so we'll just pause here and note that those all sound great, but these landmark trials have significant representation gaps that limit and should inform how confidently we generalize these findings. But back to what you just said, right, the real inflection point is MSI-high disease where, with neoadjuvant dual-checkpoint blockade, trials like NEONIPIGAS and INFINITY show pCR rates that are approaching 50% to 60%. That's not incremental progress, that's a whole new different biological reality. What does that mean? If we're saying that 50% to 60% of the people we take to the OR at the time of surgery will end up having no viable tumor, man, did we need to do a really big surgery? But the problem right now is the gold standard, I think we would mostly agree, the gold standard is pathologic complete response, and we only know that after surgery. I currently tell my patients, right, because I don't want them to be like, "Wait, we did this whole thing." I'm like, "We're going to do this surgery, and my hope is that we're going to do the surgery and there will be no cancer left in your stomach after we take out your stomach." And they're like, "But we took out my stomach and you're saying it's a good thing that there's no cancer." And yes, right now that is true because it's a measure of the efficacy of their systemic therapy. It's a measure of the biology of the disease. But should we be acting on this non-operatively? To do that, we have to find a surrogate. And the surrogate that we have to figure out is complete clinical response. And that's where we have issues with the stomach. In esophageal cancer, the preSANO protocol, which we'll talk about a little bit, validated a structured clinical response evaluation. People got really high-quality endoscopies with bite-on biopsies. They got endoscopic ultrasounds. They got fine-needle aspirations and PET-CT, and adding all of those things together, the miss rate for substantial residual disease was about 10% to 15%. That's a number we can work with. In the stomach, it's a lot more difficult anatomically just given the shape of people's stomachs. There's fibrosis, there's ulceration. A fair number of stomach and GEJ cancers have diffuse histology which makes it difficult to localize and they also have submucosal spread. Those all conceal residual disease. I had a recent case where I scoped the patient during the case, and this person had had a 4 cm ulcer prior to surgery, and I scoped and there was nothing visible. And I was elated. And on the final pathology they had a 7 cm tumor still in place. It was just all submucosal. That's the problem. I'm not a gastroenterologist, but I would have said this was a great clinical response, but because it's gastric, there was a fair amount of submucosal disease that was still there. And our imaging loses accuracy after treatment. So the gap between what looks clean clinically and what's actually there pathologically remains very wide. So I think that's why we're trying to figure it out and make it cleaner. And outside of biomarker-selected settings like MSI-high disease, in general, I'm going to skip to the end and our upshot for the paper, which is that organ preservation, I would say for gastric cancer particularly, should remain investigational. I think we're at the point where the biology is increasingly favorable, but our means of measurement is not there yet. Dr. Pedro Barata: Gotcha. So, this is a perfect segue because you did mention the SANO, just to spell it out, "Surgery As Needed for Oesophageal" trial, so SANO, perfect, I love the abbreviation. It's really catchy. It's fantastic, it's actually a well-put-together perspective effort or program applying to patients. And can you tell us how was that put together and how does that work out for patients? Dr. Ugwuji Maduekwe: Yeah, I think for those of us in the GI space, we have SANO and then we also have the OPRA for rectum. SANO for the upper GI is what takes organ preservation from theory to something that's clinically credible. The trial asked a very simple question. If a patient with a GEJ adenocarcinoma or esophageal adenocarcinoma achieved what was felt to be a clinical complete response after chemoradiation, would they actually benefit from immediate surgery? And the question was, "Can you safely observe?" And the answer was 'yes'. You could safely observe, but only if you do it right. And what does that mean? At two years, survival with active surveillance was not inferior to those who received an immediate esophagectomy. And those patients had a better early quality of life. Makes sense, right? Your quality of life with an esophagectomy versus not is going to be different. That matters a lot when you consider what the long-term metabolic and functional consequences of an esophagectomy are. The weight loss, nutritional deficiencies that can persist for years. But SANO worked because it was very, very disciplined and not permissive. You mentioned rigor. They were very elegant in their approach and there was a fair amount of rigor. So there were two main principles. The first was that surveillance was front-loaded and intentional. So they had endoscopies with biopsies and imaging every three to four months in the first year and then they progressively spaced it out with explicit criteria for what constituted failure. And then salvage surgery was pre-planned. So, the return-to-surgery pathway was already rehearsed ahead of time. If disease reappeared, take the patient to the OR within weeks. Not sit, figure out what that means, think about it a little bit and debate next steps. They were very clear about what the plan was going to be. So they've given us this blueprint for, like, watching people safely. I think what's remarkable is that if you don't do that, if you don't have that infrastructure, then organ preservation isn't really careful. It's really hopeful. And that's what I really liked about the SANO trial, aside from, I agree, the name is pretty cool. Dr. Pedro Barata: Yeah, no, that's a fantastic point. And that description is spot on. I am thinking as we go through this, where can this be adopted, right? Because, not surprisingly, patients are telling you they're doing a lot better, right, when you don't get the esophagus out or the stomach out. I mean, that makes total sense. So the question is, you know, how do you see those issues related to the logistics, right? Getting the multi-disciplinary team, getting the different assessments of CR. I guess PETs, a lot of people are getting access to imaging these days. How close do you think this is, this kind of program, to be implemented? And maybe I would assume it might need to be validated in different settings, right, including the community. How close or how far do you think you see that being applied out there versus continuing to be a niche program, watch and wait program, in dedicated academic centers? Dr. Ugwuji Maduekwe: I love this question. So I said at the top of this, I'm a health equity/health disparities researcher, and this is where I worry the most. I love the science of this. I'm really excited about the science. I'm very optimistic. I don't think this is a question of "if," I think it's a question of "when." We are going to get to a point where these conversations will be very, very reasonable and will be options. One of the things I worry about is: who is it going to be an option for? Organ preservation is not just a treatment choice, and I think what you're pointing out very rightly is it's a systems-level intervention. Look at what we just said for SANO. Someone needs to be able to do advanced endoscopy, get the patients back. We have to have the time and space to come back every three to four months. We have to do molecular testing. There needs to be multi-disciplinary review. There needs to be intensive surveillance, and you need to have rapid access to salvage surgery. Where is that infrastructure? In this country, it's mostly in academic centers. I think about the panel we had at ASCO GI, which was fantastic. And as we were having the conversation, you know, we set it up as a debate. So folks were debating either pro-surveillance or pro-surgery. But both groups, both people, were presenting outcomes based on their centers. And it was folks who were fantastic. Dr. Molena, for example, from Memorial Sloan Kettering was talking about their outcomes in esophagectomies [during our session at GI26], but they do hundreds of these cases there per year. What's the reality in this country? 70% to 80% to 90%, depending on which data you look at, of the gastrectomies in the United States occur at low-volume hospitals. Most of the patients at those hospitals are disproportionately uninsured or on government insurance, have lower income and from racial and ethnic minority groups. So if we diffuse organ preservations without the system to support it, we're going to create a two-tiered system of care where whether you have the ability to preserve your organs, to preserve bodily integrity, depends on where you live and where you're treated. The other piece of this is the biomarker testing gap. One of the things that, as you pointed out at the beginning, that's really exciting is for MSI-high tumors. Those are the patients that are most likely to benefit from immunotherapy-based organ preservation. But here's the problem. If the patient isn't tested at time of initial diagnosis before they ever see me as a surgeon, the door to organ preservation is closed before it's ever open. And testing access remains very inconsistent across academic networks. And then there's the financial toxicity piece where, for gastrectomy, pancreatectomy, I do peritoneal malignancies, more than half of those patients experience significant financial toxicity related to their cancer treatment. We're now proposing adding at least two years, that's the preliminary information, right? It's probably going to be longer. At least a couple of years of surveillance visits, repeated endoscopies, immunotherapy costs. How are we going to support patients through that? We're going to have to think about setting up navigation support, geographic solutions, what financial counseling looks like. My patient for clinic yesterday was driving to see me, and they were talking about how they were sliding because it was snowing. And they were sliding for the entire three-hour drive down here. Are we going to tell people like that that they need to drive down to, right, I work at a high-volume center, they're going to need to come here every three months, come rain or snow, to get scoped as opposed to the one-time having a surgery and not needing to have the scopes as frequently? My concern, like I said, I'm an optimist, I think it is going to work. I think we're going to figure out how to make it work. I'm worried about whether when we deploy it, we widen the already existing disparities. Dr. Pedro Barata: Gotcha, and that's a fantastic summary. And as I'm thinking also of what we've been talking in other solid tumors, which one of the following do you think is going to evolve first? So we are starting to use more MRD-based assays, which are based on blood test, whether it's a tumor-informed ctDNA or non-informed. We are also trying to get around or trying to get more information response to systemic therapies out of RNA-seq through gene expression signatures, or development of novel therapeutics which also can help you there. Which one of these areas you think you're going to help this SANO-like approach move forward, or you actually think it's actually all of the above, which makes it even more complicated perhaps? Dr. Ugwuji Maduekwe: I think it's going to be all of the above for a couple of reasons. I would say if I had to pick just one right now, I think ctDNA is probably the most promising and potentially the missing piece that can help us close the gap between clinical and pathologic response. If you achieve clinical complete response and your ctDNA is negative, so you have clinical and molecular evidence of clearance, maybe that's a low-risk patient for surveillance. If you have clinical complete response but your ctDNA remains positive, I would say you have occult molecular disease and we probably need intensified therapy, closer monitoring, not observation. I think the INFINITY trial is already incorporating ctDNA into its algorithm, so we'll know. I don't think we're at the point where it alone can drive surgical decisions. I think it's going to be a good complement to clinical response evaluation, not a replacement. The issue of where I think it's probably going to be multi-dimensional is the evidence base: who are we testing? Like, what is the diversity, what is the ancestral diversity of these databases that we're using for all of these tests? How do we know that ctDNA levels and RNA-seq expression arrays are the same across different ancestral groups, across different disease types? So I think it's probably going to be an amalgam and we're going to have to figure out some sort of algorithm to help us define it based on the patient characteristics. Like, I think it's probably different, some of this stuff is going to be a little bit different depending on where in the stomach the cancer is. And it's going to be a little bit more difficult to figure out if you have a complete clinical response in the antrum and closer to the pylorus, for example. That might be a little bit more difficult. So maybe the threshold for defining what a clinical complete response needs to be is higher because the therapeutic approach there is not quite as onerous as for something at the GE-junction. Dr. Pedro Barata: Wonderful. And I'm sure AI, whether it's digitization of the pathology from the biopsies and putting all this together, probably might play a role as well in the future.  Dr. Maduekwe, it's been fantastic. Thank you so much for sharing your insights with us and also congrats again for the really well-done review published.  For our listeners, thank you for staying with us. Thank you for your time. We will post a link to this fantastic article we discussed today in the transcript of this episode. And of course, please join us again next month on the By the Book Podcast for more insights on key advances and innovations that are shaping modern oncology. Thank you, everyone. Dr. Ugwuji Maduekwe: Thank you. Thank you for having me. Watch the ASCO GI26 session: Organ Preservation for Gastroesophageal and Gastric Cancers: Ready for Primetime? Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ugwuji Maduekwe @umaduekwemd Follow ASCO on social media:          @ASCO on X (formerly Twitter)          ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ugwuji Maduekwe: Leadership: Medica Health Research Funding: Cigna    

Cuore Sano - Relazioni sane | Pastor John Tufaro | Celebration Italia

In dieser Folge sprechen Andreas und Tim über einen tragischen Hubschrauberunfall in den USA, bei dem ein Techniker eingreifen musste, da der Pilot während des Fluges handlungsunfähig wurde. Pilots Incapacitation ist ein großes Thema in Europa und vor allem im Rahmen von Multipilot Operations und CRM. Sie analysieren die Sicherheitsaspekte von gut trainierten Crew-Mitgliedern und den großen Vorteil eines Dual Cockpits. Es haben uns einige interessante und teilweise lustige Fragen erreicht, die wir gerne beantworten. Außerdem diskutieren sie die Bedeutung der Flugtauglichkeit, regelmäßiger medizinischer Untersuchungen und psychischer Gesundheit für Piloten. Hier weisen wir darauf hin, dass die psychische Gesundheit ein extrem wichtiger Aspekt ist und sich keiner Schämen muss, wenn er sich professionelle Hilfe holt, die ihr über diverse Programme bekommt. Unter anderem gibt es beim Deutschen Hubschrauber Verband ein Peer Programm, dass genau diese Unterstützung bietet. Achtet auf euch und bleibt gesund und jetzt viel Spaß mit Abgehoben - der Hubschrauber Podcast Hier findet ihr Hilfe: [AntiSkid](https://www.antiskid.info/) [DHV](https://www.hubschrauberverband.de/)

Sano y Veracruzano - Enfermedades Invernales by Radiotelevisión de Veracruz

As our nation navigates turbulent times, what can artists do to effect change? Award-winning composer and Rochester native Adolphus Hailstork has been outspoken about this question, especially when it comes to injustices against African Americans. "These are the tragedies and triumphs of a people who have been beaten up for 400 years. Does anyone speak for them? Who writes pieces that speak for the existence of African Americans in the United States?" he asks. "I'll take on that job.'" Hailstork's work blends African, American, and European traditions. In recent years, his pieces like “A Knee on the Neck” — an oratorio in tribute to George Floyd — have made political statements. He'll be in Rochester this weekend for a choral concert in his honor, but first, he joins us on “Connections” to discuss the intersection of art and politics. This conversation is part of WXXI's celebration of Black History Month. Our guests: Adolphus Hailstork, award-winning composer Lee Wright, director of music ministry at Downtown United Presbyterian Church, and founding artistic director of First Inversion choral ensemble The selections from "A Knee on the Neck" heard in this broadcast are attributed to:Adolphus Hailstork, composerStanford Symphony Orchestra and Stanford Symphonic ChorusPaul Phillips, conductorStephen M. Sano, chorus directorSamantha Williams, mezzo-sopranoAlexander Tate, tenorWilford Kelly, baritone---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

Bienvenido a Iglesia Árbol de Vida León!   En nuevas temporadas, a menudo nos enfocamos en lo que deberíamos hacer más. Pero a veces, simplemente necesitamos simplificar. En nuestra serie, Hábitos de un Corazón Saludable, tomaremos una respiración profunda, haremos espacio para Dios y le permitiremos obrar en nuestras vidas.   Conéctate con nosotros: Iglesia Árbol de Vida León Reuniones presenciales: Domingos 10:00 am y 12:30 pm Dirección: Blvd. San Juan Bosco 3026, Cañada del Refugio, 37458 León, Gto. Sitio web: arboldevidaleon.com Instagram: https://www.instagram.com/iglesiaarboldevidaleon/ ¿Necesitas oración? Déjanos un comentario o escríbenos directamente y nuestro equipo estará orando por ti. Para solicitudes confidenciales, contáctanos por Whatsapp al 477 525 9995

Het is deadlineday in Nederland! Jos Boesveld en Sjoerd Keizer bespreken transfers uit binnen- en buitenland. Onder meer Ajax en Feyenoord komen voorbij.See omnystudio.com/listener for privacy information.

Met nog twee dagen te gaan tot de transferdeadline is het spel nu echt op de wagen. Ajax versterkte zich flink en meldde zich onder meer voor N.E.C.-middenvelder Kodai Sano. Concurrent Feyenoord moet herstelwerkzaamheden verrichten en wacht nog steeds op buitenkansjes op de transfermarkt. Dat en nog veel meer ander nieuws wordt besproken met clubwatchers Cristian Willaert en Sinclair Bischop. Learn more about your ad choices. Visit podcastchoices.com/adchoices

El CEO de Garden Hotels & Resorts, Gabriel Llobera, acoge hoy en uno de sus hoteles de Mallorca al equipo de Radioestadio Noche en su programa especial con motivo de una nueva edición de la Challenge Ciclista.

Bienvenido a Iglesia Árbol de Vida León!

Hay cosas que no sucedieron cuando pensamos que debían suceder.Oraciones que parecieron quedarse en silencio.Momentos que no llegaron. Puertas que no se abrieron.Y con el tiempo, el corazón aprende a cargar preguntas… o heridas.En este episodio comparto tres historias reales y poderosas que revelan una verdad profunda:Dios no llega tarde. Dios sana incluso lo que nunca pasó.Cuando el corazón NO se llena de resentimiento, de dolor, o de angustia, cuando decidimos soltar el “por qué no fue”y vivir con los ojos abiertos a lo que Dios sí puede hacer,entonces ocurre algo sagrado: la restitución, la restauracion interior.Este mensaje es para quienes pensaron que ya era demasiado tarde.Para quienes creyeron que ciertos capítulos no tenían solución.Para quienes están listos para sanar sin entenderlo todo. Si tú lo crees, Dios lo sana.Lo que no pasó… también puede ser redimido.Dale play. Respira. Y permite que Dios sane incluso aquello que creíste perdido. Dale Go a tu vida!

Luis Gutiérrez, vicerrector académico de la Universidad Tecmilenio, conversa con Rosalinda Ballesteros y Grecia Tovar sobre la presión de vivir con metas todo el tiempo. Juntos reflexionan sobre por qué hemos normalizado la autoexigencia constante, cuándo las metas dejan de ayudarnos y cómo replantearlas de una manera más consciente, flexible y alineada con nuestro bienestar.

Bienvenido a Iglesia Árbol de Vida León!

¿Eres de los que no puede iniciar el día sin una taza de café? Durante años nos dijeron que era un "vicio" perjudicial, pero la ciencia acaba de dar un giro de 180 grados. En este episodio, Fernanda Alvarado desglosa las investigaciones más recientes que han dejado de ver al café con recelo para considerarlo un superaliado de la salud. Descubre:El adiós al mito del cáncer: Por qué la OMS cambió su postura y qué tiene que ver la temperatura de tu bebida. El "jardín" en tu interior: Cómo el café actúa como abono para tu microbiota intestinal, alimentando bacterias clave que protegen tu cuerpo. La hora de oro: ¿Sabías que tomar café después del mediodía podría anular sus beneficios? Te decimos cuál es la ventana ideal. Filtrado vs. Espresso: Por qué el método de preparación podría ser la clave para cuidar tu colesterol. No es solo cafeína, es una dosis de longevidad en cada sorbo. ¡Dale play y transforma tu ritual mañanero!------------------Las opiniones expresadas en este canal no pretenden sustituir en ningún caso la asesoría personalizada de un profesional. EL BIEN COMER genera contenido con fines educativos, no terapéuticos. Este canal queda exento de responsabilidad por la manera en que se utilice la información aquí proporcionada. Todas las opiniones son a título personal.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 

Cada vez hay más personas que comen “mejor que nunca”… y, aun así, se sienten peor.Digestiones pesadas, cansancio, ansiedad con la comida, miedo a equivocarse, rigidez, culpa.En este episodio hablamos de la cara B de la alimentación saludable: cuando el intento de cuidarse se convierte en control, restricción y pérdida de bienestar.

Bienvenido a Iglesia Árbol de Vida León!

Nuestro guía por la sanidad pública, el nefrólogo Borja Quiroga, nos lleva hasta lo más profundo del organismo. Visitamos los laboratorios de Anatomía Patológica junto a Rosario Serrano, Médica adjunta de este departamento en el Hospital Universitario de la Princesa. Allí se encargan de cortar y analizar las muestras de órganos para detectar enfermedades como el cáncer.

Alessandro Passarella"Vangelo nero"Matsumoto SeichōEdizioni Adelphiwww.adelphi.itTraduzione dal giapponese a cura di Alessandro PassarellaBianca e maestosa, la chiesa cristiana di Musashino, quieto sobborgo di Tokyo, infonde un senso di profonda devozione, e un grande rispetto circonda i suoi sacerdoti, tutti stranieri, che vivono al riparo dalla frenesia e dalle tentazioni della grande città. Almeno fino a quando, in una placida mattina di aprile, le acque lente del vicino fiume Genpakuji non restituiranno il cadavere di una hostess. Come un ciottolo lanciato in uno stagno irradia i suoi cerchi, da quel corpo «di un bianco così puro» e dall' «aria serena» affiorerà a poco a poco un disegno oscuro, in cui ogni membro e ogni fedele della chiesa gioca la sua parte: dal giovane prete Charles Tolbecque, smanioso di assaggiare alcune libertà vietategli dall'abito talare, alla provocante Ebara Yasuko, che il parroco René Villiers visita quasi ogni notte, fino ai vertici dell'ordine, coinvolti nel commercio di misteriose casse. Risalendo con pazienza gli anelli della catena si potrebbe fare luce sull'assassinio, e su chissà cos'altro – ma non nel 1959, nell'interminabile dopoguerra che il Giappone attraversa. Per il detective Fujisawa Rokurō e per il cronista Sano la ricerca della verità sarà una lotta impari: contro le gerarchie ecclesiastiche, risolute a insabbiare il caso, e contro il potere politico, timoroso di urtare le nazioni da cui provengono i religiosi. Specchio di un Giappone ferito ma animato da sussulti di orgoglio, Vangelo nero è uno dei libri più singolari di Matsumoto, dove le atmosfere del noir si saldano al rigore dell'inchiesta giornalistica, in una trama così prossima alla realtà da risultare implausibile.Seicho Matsumoto (1909-1992) è stato un giornalista e scrittore giapponese. Autore molto conosciuto in patria e vincitore del premio Akutagawa nel 1953, ha scritto oltre 300 romanzi e diversi racconti.Da alcuni definito il “Simenon giapponese” è stato pubblicato per tre volte nel Giallo Mondadori: La Morte è in Orario del 1957 è l'opera più conosciuta, seguita da Come sabbia tra le dita del 1961 e Il palazzo dei matrimoni del 1998. Le tematiche dei suoi gialli affondano spesso le radici nei problemi sociali giapponesi, il tutto unito ad una predilezione per l'indagine strettamente logica ed intuitiva. Nel 2018 Adelphi ha pubblicato Tokyo Express, apparso nell'edizione originale nel 1958, da cui è stato tratto nel 2007 il film Ten to sen, con Takeshi Kitano. Tra gli altri titoli, Un posto tranquillo (Adelphi, 2020), La ragazza del Kyüshü (Adelphi, 2021), Il dubbio (Adelphi,2022), L'attesa (Adelphi, 2024).Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.IL POSTO DELLE PAROLEascoltare fa pensarehttps://ilpostodelleparole.it/

Te compartimos la meditación del día tomada de Lc 5, 12-16.Para más recursos para encontrarte con Dios en la oración, visita nuestra página web www.meditaciondeldia.com, nuestra tienda www.meditaciondeldia.com/tienda/ o síguenos en Instagram @meditaciondeldia_ y compártenos tu opinión!Conviértete en donante de Meditación del Día en este enlace: https://bit.ly/DonarMdDMaría Reina de los Apóstoles, ¡enséñanos a orar!Este podcast es parte de JuanDiegoNetwork.com¡Gracias por escucharnos!

¿Sabías que ciertos hábitos cotidianos influyen más de lo que imaginamos en cómo envejece nuestro cerebro? ¿Y que la prevención de las enfermedades neurodegenerativas empieza en la infancia? Si quieres mantener el cerebro sano y joven este episodio te interesa. Hablamos con Mercè Boada, neuróloga con más 40 años de experiencia en enfermedades neurodegenerativas, premio Alzheimer de la Sociedad Española de Neurología y especialista pionera en abrir el primer centro de día para personas con demencia en nuestro país: ACE Alzheimer Centre en Barcelona. See omnystudio.com/listener for privacy information.

¿Crees que estás "destinado" a enfermarte porque tus padres o abuelos lo hicieron?

Bienvenido a Iglesia Árbol de Vida León!

In Tekengeld legt Bennett van Fessem uit wat er allemaal mis gaat bij de Nederlandse trainingskampen in Spanje, gokken Nijmegenaren Teun de Boer en Sjors Grol dat Kodai Sano in Nijmegen blijft en gaat het over de recordtransfer van Jizz Hornkamp naar AZ. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Prédica impartida por el pastor Ever Molina a la Luz de la Palabra de Dios.

Baadigoob cusub oo dib loogu raadinayo diyaaraddii Malaysia Airlines ee number-ka duulimaadkeedu ahaa MH370 ayaa dib loo bilaabay Talaadadii, December 30 2025, in ka badan toban sano kaddib markii ay diyaaraddaasi luntay. Diyaaraddaas ayaa ka duushay magaalada Kuala Lumpur kuna sii jeedday magaalada Beijing, iyadoo ay saarnaayeen 239 qof.

In de Voetbalpraat van 30 december bespreken Wouter Bouwman, Anco Jansen, Kees Kwakman en Leo Driessen het laatste voetbalnieuws. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Het voetbaljaar 2025 is op zijn einde gekomen. Valentijn Driessen, Mike Verweij en Pim Sedee blikken nog een keer terug op het afgelopen Eredivisie-weekend. Feyenoord werd in eigen huis overrompeld door FC Twente, het was volgens de heren van Kick-off een wonder dat de ploeg van Robin van Persie een punt overhield aan de confrontatie. Welke aankopen moet Feyenoord doen om de tweede seizoenshelft beter voor de dag te komen? PSV lijkt Joey Veerman kwijt te raken in de winterstop, is Sano van NEC een ideale opvolger? En: veel scheidsrechterlijke beslissingen onder de loep in deze laatste aflevering van 2025. See omnystudio.com/listener for privacy information.

info: https://radio.syg.ma/episodes/peripherie-19-akhira-sano https://akhirasano.com

¿Te sientes cansada de ser fuerte todo el tiempo? En Somos Aliadas, Paola Rojas conversa con Nathaly Marcus sobre “Sano, salvaje y sabio” y la importancia de soltar la dureza, permitirte recibir y hacer de tu salud un ritual cotidiano. Learn more about your ad choices. Visit megaphone.fm/adchoices

En este episodio hablamos de cómo se ve y se siente un amor estable e intencional. Conversamos de lo que cambia cuando hay comunicación y ganas de construir una relación porque el amor sano no se consigue: se construye, se aprende y se elige todos los días.Join the club!--0:00 - Intro4:00 - Update emocional + ansiedad de Paola7:20 - Nuevo término del dating “Boysober”14:40 - Cómo se ve y siente un amor sano--Episodios extra todos los Viernes y contenido exclusivo https://www.patreon.com/alcontrariopodcast Tu voz es súper importante para nosotras! Ingresa aquí - https://forms.gle/JYQbq8tDnf9NRaRS7 Link del buzón secreto - https://forms.gle/ZBsMfe2cBhhJr8aM8

La curación tiene que ser un trabajo interior

En el caso real de hoy te cuento la historia de una paciente que vino a consulta con un objetivo muy habitual: perder 4-5 kilos y “comer un poco mejor”. Lo que parecía una búsqueda inocente de orden y bienestar terminó revelando algo mucho más profundo: una relación rígida, ansiosa y completamente dominada por la necesidad de hacerlo todo “perfecto”.A través de su relato verás cómo la rigidez, el miedo a improvisar, el exceso de control, el ejercicio compensatorio, el mal descanso y la culpa después de cada “desliz” nos llevaron a identificar un cuadro de ortorexia que ella misma no había reconocido.En este episodio te explico:Qué señales me hicieron sospechar que no era una simple mejora de hábitos.El momento exacto que encendió todas las alarmas.Cómo era su alimentación, su ejercicio y su sueño… y por qué eso mantenía la ansiedad.Por qué la ansiedad no era falta de nutrientes sino falta de flexibilidad.Cómo trabajamos desde nutrición y por qué fue imprescindible derivarla también a psicología.La evolución y lo que realmente necesitaba para encontrarse mejor.Un caso que demuestra que comer sano no siempre es sinónimo de salud y que, a veces, la clave no está en comer más limpio, sino en comer con más libertad.Conviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/comiendo-con-maria-nutricion--2497272/support.

El Dr. Walter Riso nos explica las diferencias entre el amor y la pasión. ¿Cómo se complementan el eros y la ternura? Escúchalo en este episodio.Escucha Pregúntale a César en el podcast de Por el Placer de Vivir con César Lozano, en Uforia App, Apple Podcasts, Spotify, ViX y el canal de YouTube de Uforia Podcasts, o donde sea que escuches tus podcasts. ¿Cómo te sentiste al escuchar este Episodio? Déjanos tus comentarios, suscríbete y cuéntanos cuáles otros temas te gustaría oír en #porelplacerdevivir